COMMON STOCK PURCHASE WARRANT DERMATA THERAPEUTICS, INC.Common Stock Purchase Warrant • February 4th, 2022 • Dermata Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ____, 20271 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Dermata Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), up to ___ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder o
PRE-FUNDED COMMON STOCK PURCHASE WARRANT DERMATA THERAPEUTICS, INC.Pre-Funded Common Stock Purchase Warrant • February 4th, 2022 • Dermata Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Dermata Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
DERMATA THERAPEUTICS, INC. and DIRECT TRANSFER, LLC, as Warrant Agent Warrant Agency Agreement Dated as of __, 2022 WARRANT AGENCY AGREEMENTWarrant Agency Agreement • February 4th, 2022 • Dermata Therapeutics, Inc. • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of ____, 2022 (“Agreement”), between Dermata Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Direct Transfer LLC (the “Warrant Agent”).
DERMATA THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 4th, 2022 • Dermata Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Dermata Therapeutics, Inc., a company incorporated under the laws of Delaware (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • February 4th, 2022 • Dermata Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Employment Agreement (the “Amendment”) is made and entered into between Dermata Therapeutics, Inc. (the “Company”) and Maria Bedoya Toro Munera (the “Executive”) effective as of January 1, 2022 (the “Effective Date”).
SECOND AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • February 4th, 2022 • Dermata Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to Employment Agreement (the “Second Amendment”) is made and entered into between Dermata Therapeutics, Inc. (the “Company”) and Christopher Nardo (the “Executive”) effective as of January 1, 2022 (the “Effective Date”).
